Haemodynamic effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. 1995

H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
Department of Medicine Taipei, Veterans General Hospital, Taiwan, Republic of China.

The haemodynamic effects of a combination of propranolol and clonidine were evaluated in 20 patients with post-hepatitic cirrhosis. Haemodynamic measurements were taken before and 30 min after an intravenous injection of 0.1 mg/kg of propranolol. Thereafter, each patient was given an oral dose of 150 micrograms of clonidine and re-measured 60 min later. In this series, eight patients were defined as 'non-responders' (a decrease in hepatic venous pressure gradient of < 10%) after propranolol treatment. Of both the responders and non-responders, propranolol caused expected decreases in the cardiac index and heart rate while mean arterial pressure remained unchanged. Of the propranolol responders, a significant decrease in hepatic venous pressure gradient was observed. After the addition of clonidine, in both the responders and non-responders there was a further decrease in hepatic venous pressure gradient with a concurrent drop in mean arterial pressure, but cardiac index and heart rate remained unaltered. In conclusion, the combination of propranolol and clonidine in post-hepatitic cirrhotic patients enhanced the reduction of portal pressure achieved by propranolol alone. The beneficial effects of the combination of the two in the reduction of portal pressure appeared to be similar in both the propranolol responders and non-responders. However, the drop in mean arterial pressure following the addition of clonidine may be hazardous to cirrhotic patients.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006503 Hepatic Veins Veins which drain the liver. Hepatic Vein,Vein, Hepatic,Veins, Hepatic
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection

Related Publications

H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
February 2001, European journal of gastroenterology & hepatology,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
May 1996, British journal of clinical pharmacology,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
August 1988, Scandinavian journal of gastroenterology,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
May 1977, Journal of the Indian Medical Association,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
January 2007, Clinical hemorheology and microcirculation,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
September 1991, Journal of hepatology,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
May 2010, Thrombosis research,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
November 1999, Alimentary pharmacology & therapeutics,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
October 1989, Canadian journal of physiology and pharmacology,
H C Lin, and Y T Tsai, and M C Yang, and M C Hou, and F Y Lee, and L S Chen, and S D Lee
November 1955, Archives des maladies de l'appareil digestif et des maladies de la nutrition,
Copied contents to your clipboard!